Precision BioSciences (DTIL) Goodwill: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.30-0.01 (-0.24%)

Delayed quote: Oct 6, 2026, 12:00 PM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

Period	Goodwill	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$0	N/A	N/A
Q1 FY2026Period end 2026-03-31	$0	N/A	N/A
Q4 FY2025Period end 2025-12-31	$0	N/A	N/A
Q3 FY2025Period end 2025-09-30	$0	N/A	N/A
Q2 FY2025Period end 2025-06-30	$0	N/A	N/A
Q1 FY2025Period end 2025-03-31	$0	N/A	N/A
Q4 FY2024Period end 2024-12-31	$0	N/A	N/A
Q3 FY2024Period end 2024-09-30	$0	N/A	N/A
Q2 FY2024Period end 2024-06-30	$0	N/A	N/A
Q1 FY2024Period end 2024-03-31	$0	N/A	N/A
Q4 FY2023Period end 2023-12-31	$0	N/A	N/A
Q3 FY2023Period end 2023-09-30	$0	N/A	N/A
Q2 FY2023Period end 2023-06-30	$0	N/A	N/A
Q1 FY2023Period end 2023-03-31	$0	N/A	N/A
Q4 FY2022Period end 2022-12-31	$0	N/A	N/A
Q3 FY2022Period end 2022-09-30	$0	N/A	N/A
Q2 FY2022Period end 2022-06-30	$0	N/A	N/A
Q1 FY2022Period end 2022-03-31	$0	N/A	N/A
Q4 FY2021Period end 2021-12-31	$0	N/A	N/A
Q3 FY2021Period end 2021-09-30	$0	N/A	N/A
Q2 FY2021Period end 2021-06-30	$0	N/A	N/A
Q1 FY2021Period end 2021-03-31	$0	N/A	N/A
Q4 FY2020Period end 2020-12-31	$0	N/A	N/A
Q3 FY2020Period end 2020-09-30	$0	N/A	N/A
Q2 FY2020Period end 2020-06-30	$0	N/A	N/A
Q1 FY2020Period end 2020-03-31	$0	N/A	N/A
Q4 FY2019Period end 2019-12-31	$0	N/A	N/A
Q3 FY2019Period end 2019-09-30	$0	N/A	N/A
Q2 FY2019Period end 2019-06-30	$0	N/A	N/A
Q1 FY2019Period end 2019-03-31	$0	N/A	N/A
Q4 FY2018Period end 2018-12-31	$0	N/A	N/A

Goodwill

DTIL Goodwill

Current Goodwill

QoQ Growth

Historical Data

Quarterly Goodwill History

Related Metrics